Evaluate Vantage Homepage
AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Medtech
More, but slower, medtech approvals
If the second half maintains the pace, 2023 could see the most device approvals for a decade.
Medtech dealmaking grinds almost to a halt
M&A moves are down, venture rounds few and IPOs nonexistent.
Company Events
Big readouts ahead for small biotechs
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Interviews
Home Bioscience eyes fresh funds
With a focus on France and Germany, the company builder is also closing in on its final two targets.
Delays fail to Quell Treg interest
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.